Levosimendan, a Promising Pharmacotherapy in Cardiogenic Shock: A Comprehensive Review
Cardiogenic shock (CS) is a critical condition with high mortality rate, as the current management of CS presents significant challenges. Exploration of more effective therapies is necessitated. This review article comprehensively examines the efficacy and safety of levosimendan in the management of...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Radcliffe Medical Media
2024-11-01
|
| Series: | European Cardiology Review |
| Online Access: | https://www.ecrjournal.com/articleindex/ecr.2024.16 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846122328894734336 |
|---|---|
| author | Hendri Susilo Fan Maitri Aldian Citrawati Dyah Kencono Wungu Mochamad Yusuf Alsagaff Henry Sutanto Chaq El Chaq Zamzam Multazam |
| author_facet | Hendri Susilo Fan Maitri Aldian Citrawati Dyah Kencono Wungu Mochamad Yusuf Alsagaff Henry Sutanto Chaq El Chaq Zamzam Multazam |
| author_sort | Hendri Susilo |
| collection | DOAJ |
| description | Cardiogenic shock (CS) is a critical condition with high mortality rate, as the current management of CS presents significant challenges. Exploration of more effective therapies is necessitated. This review article comprehensively examines the efficacy and safety of levosimendan in the management of CS. By synthesising evidence from numerous studies, a comparison of levosimendan over traditional inotropic agents, such as enoximone, dobutamine, dopamine and norepinephrine, is highlighted. The unique mechanism of action of levosimendan enhances myocardial contractility without increasing oxygen demand, offering a promising alternative for patients with CS. This review also delves into comparative studies that demonstrate the superiority of levosimendan in improving survival rates, haemodynamic parameters, and reducing the incidence of CS complications. Safety profiles and adverse effects are critically assessed to provide a balanced view of the therapeutic window provided by levosimendan. The review concludes that levosimendan is a valuable addition to the therapeutic strategy against CS, with the potential to improve patient outcomes. |
| format | Article |
| id | doaj-art-778e916419b74a9f99cdfa8020e34337 |
| institution | Kabale University |
| issn | 1758-3756 1758-3764 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Radcliffe Medical Media |
| record_format | Article |
| series | European Cardiology Review |
| spelling | doaj-art-778e916419b74a9f99cdfa8020e343372024-12-14T16:05:24ZengRadcliffe Medical MediaEuropean Cardiology Review1758-37561758-37642024-11-011910.15420/ecr.2024.16Levosimendan, a Promising Pharmacotherapy in Cardiogenic Shock: A Comprehensive ReviewHendri Susilo0Fan Maitri Aldian1Citrawati Dyah Kencono Wungu2Mochamad Yusuf Alsagaff3Henry Sutanto4Chaq El Chaq Zamzam Multazam5Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia; Department of Cardiology and Vascular Medicine, Universitas Airlangga Hospital, Surabaya, Indonesia;Faculty of Medicine, Universitas Airlangga, Surabaya, IndonesiaDepartment of Physiology and Medical Biochemistry, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia; Institute of Tropical Disease, Universitas Airlangga, Surabaya, IndonesiaDepartment of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia; Department of Cardiology and Vascular Medicine, Universitas Airlangga Hospital, Surabaya, Indonesia;Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, IndonesiaNational Heart and Lung Institute, Faculty of Medicine, Imperial College London, London, UKCardiogenic shock (CS) is a critical condition with high mortality rate, as the current management of CS presents significant challenges. Exploration of more effective therapies is necessitated. This review article comprehensively examines the efficacy and safety of levosimendan in the management of CS. By synthesising evidence from numerous studies, a comparison of levosimendan over traditional inotropic agents, such as enoximone, dobutamine, dopamine and norepinephrine, is highlighted. The unique mechanism of action of levosimendan enhances myocardial contractility without increasing oxygen demand, offering a promising alternative for patients with CS. This review also delves into comparative studies that demonstrate the superiority of levosimendan in improving survival rates, haemodynamic parameters, and reducing the incidence of CS complications. Safety profiles and adverse effects are critically assessed to provide a balanced view of the therapeutic window provided by levosimendan. The review concludes that levosimendan is a valuable addition to the therapeutic strategy against CS, with the potential to improve patient outcomes.https://www.ecrjournal.com/articleindex/ecr.2024.16 |
| spellingShingle | Hendri Susilo Fan Maitri Aldian Citrawati Dyah Kencono Wungu Mochamad Yusuf Alsagaff Henry Sutanto Chaq El Chaq Zamzam Multazam Levosimendan, a Promising Pharmacotherapy in Cardiogenic Shock: A Comprehensive Review European Cardiology Review |
| title | Levosimendan, a Promising Pharmacotherapy in Cardiogenic Shock: A Comprehensive Review |
| title_full | Levosimendan, a Promising Pharmacotherapy in Cardiogenic Shock: A Comprehensive Review |
| title_fullStr | Levosimendan, a Promising Pharmacotherapy in Cardiogenic Shock: A Comprehensive Review |
| title_full_unstemmed | Levosimendan, a Promising Pharmacotherapy in Cardiogenic Shock: A Comprehensive Review |
| title_short | Levosimendan, a Promising Pharmacotherapy in Cardiogenic Shock: A Comprehensive Review |
| title_sort | levosimendan a promising pharmacotherapy in cardiogenic shock a comprehensive review |
| url | https://www.ecrjournal.com/articleindex/ecr.2024.16 |
| work_keys_str_mv | AT hendrisusilo levosimendanapromisingpharmacotherapyincardiogenicshockacomprehensivereview AT fanmaitrialdian levosimendanapromisingpharmacotherapyincardiogenicshockacomprehensivereview AT citrawatidyahkenconowungu levosimendanapromisingpharmacotherapyincardiogenicshockacomprehensivereview AT mochamadyusufalsagaff levosimendanapromisingpharmacotherapyincardiogenicshockacomprehensivereview AT henrysutanto levosimendanapromisingpharmacotherapyincardiogenicshockacomprehensivereview AT chaqelchaqzamzammultazam levosimendanapromisingpharmacotherapyincardiogenicshockacomprehensivereview |